Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Male breast cancer, drawn from the whole corpus: 1 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Men are still under-enrolled in breast cancer trials; regulatory guidance and label harmonisation are the response.
Aromatase inhibitor efficacy and the need for GnRH co-treatment rest on small studies; registries are collecting outcomes.
Later diagnosis from low awareness; education campaigns and rapid referral pathways are the levers.
Adjuvant endocrine adherence and side effects in men are poorly studied.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 10 changes by month →When this page itself was last checked or edited.
iDFS HR 0.
Trial included men.
Tamoxifen for five to ten years; aromatase inhibitor only with GnRH agonist suppression if tamoxifen is contraindicated.
Mastectomy (or breast conservation where feasible) with sentinel node biopsy; adjuvant radiotherapy by the same criteria as women; chemotherapy and HER2-directed therapy as indicated. (NCCN Category 2A)
First ASCO guideline on male breast cancer; FDA guidance on including men in breast cancer drug development.